Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (Ethanol) in healthy human subjects

Clinical Pharmacokinetics

Volumn 49, Issue 7, 2010, Pages 449-454

  La Porte, Charles ^a,b   Voduc, Nha ^b   Zhang, Guijun ^a   Seguin, Isabelle ^a   Tardiff, Danielle ^a   Singhal, Neera ^a,b   Cameron, D William ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Alcohol; Antihyperlipidaemics; Antineoplastics; Antioxidants; Food; Pharmacokinetics; Quercetin; Research and development; Resveratrol; Stilbenes

Indexed keywords

ALCOHOL; BILIRUBIN; PARACETAMOL; POTASSIUM; QUERCETIN; RESVERATROL; TRANSMAX; UNCLASSIFIED DRUG; DRUG COMBINATION; STILBENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MORNING DOSAGE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; DIET; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG TOLERANCE; MIDDLE AGED;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DIARRHEA; DIET; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG TOLERANCE; ETHANOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOKINETICS; QUERCETIN; STILBENES; TANDEM MASS SPECTROMETRY;

EID: 77953353711     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11531820-000000000-00000     Document Type: Article

References (15)

1. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect 2003 Jun; 16 (5): 299-307
2. Guarente L, Picard F. Calorie restriction: the SIR2 connection. Cell 2005 Feb 25; 120 (4): 473-482
3. Soleas GJ, Grass L, Josephy PD, et al. A comparison of the anticarcinogenic propertiesoffour red wine polyphenols. Clin Biochem 2006 May; 39(5): 492-497
4. Whitsett Jr TG, Lamartiniere CA. Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. Expert Rev Anticancer Ther 2006 Dec; 6 (12): 1699-1706
5. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006 Sep 1; 545 (1): 51-64
6. Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006; 6: 35
7. Wang Q, Xu J, Rottinghaus GE, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002 Dec 27; 958 (2): 439-447
8. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics transresveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995 Mar 31; 235 (2): 207-219
9. Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004 Dec; 32 (12): 1377-1382
10. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic studyin healthy volunteersof resveratrol, apotential cancer chemo-preventive agent. Cancer Epidemiol Biomarkers Prev 2007 Jun; 16 (6): 1246-1252
11. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009 May; 53 (S1): S7-15
12. Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008 Nov; 46 (11): 564-570
13. De Santi C, Pietrabissa A, Spisni R, et al. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xeno-biotica 2000 Sep; 30 (9): 857-866
14. Goldberg DM, YanJ, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003 Feb; 36 (1): 79-87
15. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy ofresveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 2003 Oct; 12 (10): 953-957